Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility | Markets Insider
At 17.6% CAGR of CIS and Central Eastern Dermal Fillers Market Forecast by 2029